Detection of cancer in radical prostatectomy specimens with no residual carcinoma in the initial review of slides

American Journal of Surgical Pathology

Volumn 33, Issue 1, 2009, Pages 120-125

  Duffield, Amy S ^a   Epstein, Jonathan I ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Needle biopsy; Prostate cancer; Radical prostatectomy; Vanishing cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BASAL CELL; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; TUMOR BIOPSY; ADENOCARCINOMA; CYTOLOGY; METHODOLOGY; MIDDLE AGED; PROSTATE TUMOR;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; CYTOLOGICAL TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 59149098565     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318185723e     Document Type: Article

References (18)

1. Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology. 2007;69:103-107.
2. Boccon-Gibod LM, Dumonceau O, Toublanc M, et al. Micro-focal prostate carcinoma: a comparison of biopsy and radical prostatectomy specimen features. Eur Urol. 2005;48:895-899.
3. Bostwick DG, Bostwick KC. "Vanishing" prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int. 2004;94:57-58.
4. Cao D, Hafez M, Berg K, et al. Little of no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen? Am J Surg Path. 2005;29:467-473.
5. Chen ME, Troncoso P, Johnston D. Prostate cancer detection, relationship to prostate size. Urology. 1999;530:764-768.
6. Descazeaud A, Zerbib M, Flam T, et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol. 2006;50:1248-1253.
7. DiGieuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Path. 1997;21:174-178.
8. Epstein JI, Walsh PC, Eggleston JC. Prognosis of untreated stage A1 prostate carcinoma: a study of 94 cases with extended follow-up. J Urol. 1986;136:837-839.
9. Goldstein NS, Begin LR, Grody WW, et al. Minimal or no cancer in radical prostatectomy specimens. Am J Surg Path. 1995;19: 1002-1009.
10. Herkommer K, Keufer R, Gschwend JE, et al. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol. 2004;45:36-41.
11. Humphrey P. Complete histologic serial sectioning of a prostate gland with adenocarcinoma. Am J Surg Path. 1993;17:468-472.
12. Kollermann J, Feek U, Muller H, et al. Nondetected tumor (pT0) after prolonged, neoadjuvant treatment of localized prostatic carcinoma. Eur Urol. 2000;38:714-720.
13. Larsen MP, Carter HB, Epstein JI. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent, or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stage A2 and B disease. J Urol. 1991;146:1059-1063.
14. Mazzucchelli R, Barbisan F, Taliabracci A, et al. Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. Virchows Arch. 2007;450:371-378.
15. Poulos CK, Daggy JK, Cheng L. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens. Cancer. 2004;101:527-532.
16. Poulos CK, Daggy JK, Cheng L. Postoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. Mod Pathol. 2005;18:228-234.
17. Stamey TA, Johnston IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol. 2002;167:103-111.
18. Zynger DL, Dumov ND, Yang XJ. Trends in carcinoma volume in 1612 radical prostatectomies: increased evidence of minimal and no residual cancer. Mod Pathol. 19(suppl 3):90A.